Cargando…
Clinical Trials Targeting Secondary Damage after Traumatic Spinal Cord Injury
Spinal cord injury (SCI) often causes loss of sensory and motor function resulting in a significant reduction in quality of life for patients. Currently, no therapies are available that can repair spinal cord tissue. After the primary SCI, an acute inflammatory response induces further tissue damage...
Autores principales: | Khaing, Zin Z., Chen, Jessica Y., Safarians, Gevick, Ezubeik, Sohib, Pedroncelli, Nicolas, Duquette, Rebecca D., Prasse, Tobias, Seidlits, Stephanie K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960771/ https://www.ncbi.nlm.nih.gov/pubmed/36835233 http://dx.doi.org/10.3390/ijms24043824 |
Ejemplares similares
-
Gene Delivery Strategies to Promote Spinal Cord Repair
por: Walthers, Christopher M, et al.
Publicado: (2015) -
CCL3 contributes to secondary damage after spinal cord injury
por: Pelisch, Nicolas, et al.
Publicado: (2020) -
Injectable, macroporous scaffolds for delivery of therapeutic genes to the injured spinal cord
por: Ehsanipour, Arshia, et al.
Publicado: (2021) -
Correction to: CCL3 contributes to secondary damage after spinal cord injury
por: Pelisch, Nicolas, et al.
Publicado: (2021) -
Ruxolitinib attenuates secondary injury after traumatic spinal cord injury
por: Qian, Zhan-Yang, et al.
Publicado: (2022)